Technical Analysis for NVCR - NovoCure Limited

Grade Last Price % Change Price Change
grade A 68.26 -0.68% -0.47
NVCR closed down 0.68 percent on Wednesday, July 17, 2019, on approximately normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical NVCR trend table...

Date Alert Name Type % Chg
Overbought Stochastic Strength 0.00%
Overbought Stochastic Strength -0.68%
New 52 Week High Strength -0.63%
Overbought Stochastic Strength -0.63%
Upper Bollinger Band Walk Strength -0.91%
Inside Day Range Contraction -0.91%
Overbought Stochastic Strength -0.91%
Upper Bollinger Band Touch Strength -0.91%
New 52 Week Closing High Bullish -1.27%
Pocket Pivot Bullish Swing Setup -1.27%

Older signals for NVCR ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
NovoCure Limited develops and commercializes treatment for solid tumor cancers therapy called the tumor treating fields (TTFields). The company markets its proprietary therapy, TTFields delivery system under the Optune name for use as a monotherapy treatment for adult patients with glioblastoma brain cancer. NovoCure Limited also conducts clinical trials for the use of TTFields in brain metastases, advanced non-small cell lung cancer, pancreatic cancer, ovarian cancer, and mesothelioma. The company markets its products in the United States, as well as in European Union member states, Switzerland, and Japan. NovoCure Limited was founded in 2000 and is based in Saint Helier, Channel Islands.
Medicine Cancer Clinical Medicine Oncology Tumor Non Small Cell Lung Cancer Ovarian Cancer Glioblastoma Pancreatic Cancer Aging Associated Diseases Brain Tumor European Union Solid Tumor Cancers Mesothelioma
Is NVCR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 69.75
52 Week Low 26.02
Average Volume 644,268
200-Day Moving Average 46.3803
50-Day Moving Average 56.9018
20-Day Moving Average 63.506
10-Day Moving Average 66.637
Average True Range 2.0904
ADX 43.41
+DI 35.4422
-DI 9.0457
Chandelier Exit (Long, 3 ATRs ) 63.4788
Chandelier Exit (Short, 3 ATRs ) 61.0212
Upper Bollinger Band 71.1558
Lower Bollinger Band 55.8562
Percent B (%b) 0.81
BandWidth 24.091582
MACD Line 3.4948
MACD Signal Line 3.231
MACD Histogram 0.2637
Fundamentals Value
Market Cap 6.07 Billion
Num Shares 88.9 Million
EPS -1.09
Price-to-Earnings (P/E) Ratio -62.62
Price-to-Sales 13.08
Price-to-Book 13.88
PEG Ratio -0.41
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 70.15
Resistance 3 (R3) 70.25 69.73 69.84
Resistance 2 (R2) 69.73 69.25 69.68 69.73
Resistance 1 (R1) 68.99 68.95 68.73 68.89 69.62
Pivot Point 68.47 68.47 68.34 68.42 68.47
Support 1 (S1) 67.73 67.99 67.47 67.63 66.90
Support 2 (S2) 67.21 67.69 67.16 66.79
Support 3 (S3) 66.47 67.21 66.69
Support 4 (S4) 66.37